TNFi联合甲氨蝶呤与三联疗法治疗类风湿关节炎的严重感染风险比较:队列研究
本研究基于Truven MarketScan(2003-2014)理赔数据,比较类风湿关节炎患者启动TNFi联合甲氨蝶呤(45,208例)与三联疗法(1,387例)的严重感染风险。经倾向评分分层加权后,任何严重感染的加权HR为1.23(95%CI 0.87-1.74),细菌感染HR为1.41(95%CI 0.85-2.34),带状疱疹HR为0.80(95%CI 0.55-1.18),置信区间较宽,未观察到显著差异。
要点
- TNFi联合MTX与三联疗法相比,任何严重感染风险无显著差异(HR 1.23,95%CI 0.87-1.74)。
- 细菌感染和带状疱疹的次要结局风险同样无显著差异,但置信区间较宽。
- 真实世界队列中两组严重感染发生率分别为2.46和2.03每100人年。
核心结论
- 在真实世界类风湿关节炎队列中,启动TNFi联合MTX与三联疗法相比,任何严重感染、细菌感染或带状疱疹的风险未见实质性差异,但置信区间较宽。
研究设计与样本
- 基于Truven MarketScan(2003-2014)理赔数据的队列研究,比较接受MTX的RA患者加用TNFi(TNFi+MTX组)与加用羟氯喹和柳氮磺吡啶(三联疗法组)。
- 采用倾向评分分层加权调整基线混杂,加权Cox比例风险模型估计HR和95%CI。
- 经倾向评分分层加权后,纳入45,208例TNFi+MTX启动者和1,387例三联疗法启动者,平均年龄53岁,女性占70%。
主要发现
- 任何严重感染的发病率在TNFi+MTX组为2.46每100人年,三联疗法组为2.03每100人年。
- 倾向评分分层加权后,任何严重感染的HR为1.23(95%CI 0.87-1.74)。
- 次要结局中,细菌感染的加权HR为1.41(95%CI 0.85-2.34),带状疱疹的加权HR为0.80(95%CI 0.55-1.18)。
临床怎么用
- 在真实世界RA患者中,选择TNFi联合MTX或三联疗法时,严重感染风险未见显著差异,但需注意置信区间较宽,个体化决策仍需结合患者具体情况。
局限性
- 观察性队列设计可能残留混杂。
- 三联疗法组样本量较小(1,387例),置信区间较宽,可能掩盖潜在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of serious infections between the use of tumor necrosis factor inhibitors (TNFi) plus methotrexate (MTX) versus triple therapy among rheumatoid arthritis (RA) patients in a real-world setting. METHODS: Using claims data from Truven MarketScan (2003-2014), we conducted a cohort study to compare RA patients receiving MTX who added a TNFi (TNFi plus MTX group) versus MTX plus hydroxychloroquine and sulfasalazine (triple therapy group). The primary outcome was any serious infection (i.e., a composite end point of hospitalized bacterial and opportunistic infections or herpes zoster). Secondary outcomes were individual components of the composite end point. To adjust for baseline confounding, we used propensity score (PS)-based fine stratification and weighting. A weighted Cox proportional hazards model estimated the hazard ratio (HR) and 95% confidence interval (95% CI) of the outcomes. RESULTS: After PS stratification (PSS) and weighting, we included a total of 45,208 TNFi plus MTX initiators and 1,387 triple therapy initiators. Mean age was 53 years and 70% were female. The incidence rate of any serious infection per 100 person-years was 2.46 in the TNFi plus MTX group and 2.03 in the triple therapy group. The PSS-weighted HR for any serious infection comparing TNFi plus MTX versus triple therapy was 1.23 (95% CI 0.87-1.74). For the secondary outcomes, the PSS-weighted HR was 1.41 (95% CI 0.85-2.34) for bacterial infection and 0.80 (95% CI 0.55-1.18) for herpes zoster. CONCLUSION: In this real-world cohort of RA patients, we noted no substantially different risk of any serious infection, bacterial infection, or herpes zoster after initiating TNFi plus MTX versus triple therapy, although CIs were wide.
引用
- Kang EH, Jin Y, Tong AY, et al. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. Arthritis Care Res (Hoboken). 2020. PMID: 31376333. doi:10.1002/acr.24038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。